All In Biotech

Free tool

FAERS Monitor: Steglujan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209805 or its brand name (Steglujan, Ertugliflozin, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.

Reports

120

Serious

75

63% of reports

Hospitalization

45

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea16
  • bradycardia15
  • vomiting15
  • covid-1913
  • covid-19 pneumonia12
  • gastrointestinal haemorrhage12
  • blood glucose increased10
  • cardiac failure9
  • product dose omission issue9
  • hypertension6
  • no adverse event6
  • ketoacidosis5
  • rash5
  • alopecia4
  • diabetic neuropathy4

Reports by year received

View as table
YearReports
20186
201928
202030
202113
20224
202320
202414
20252
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
covid-19 pneumoniaSignal12178.3104.21,941
diabetic neuropathySignal4141.754.1427
ketoacidosisSignal5117.249.7465
bradycardiaSignal1549.630.9668
gastrointestinal haemorrhageSignal1225.214.7256
cardiac failureSignal919.710.5142
covid-19Signal1313.07.8133
blood glucose increasedSignal109.35.167
no adverse eventSignal65.82.719
vomitingSignal155.63.553
product dose omission issueSignal95.42.928
hypertensionSignal65.02.315
dyspnoeaSignal165.03.148
alopeciaSignal43.61.45
rash52.00.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.